About Us
About JWE
JWE (Beijing) Science Technology, Inc. focuses on innovative services in immune target research and precision therapy. We apply cutting-edge immunology technologies and bioinformatics approaches to drug development and clinical translation, providing efficient and cost-effective solutions for major diseases.
Our team brings together experts from Stanford University, Tsinghua University, Peking University, and other top research institutions. Through proprietary technologies including yeast display, TCR epitope analysis, and CAR epitope screening, we enable precise target validation and clinical translation. JWE maintains close collaborations with leading research institutes and enterprises worldwide to jointly advance immune target research and precision therapeutics.
- Yeast Display HLA System for efficient epitope validation
- Accurate TCR/L epitope analysis and prediction
- Antibody epitope and CAR-T epitope screening services
- Interdisciplinary expert team with Stanford / Tsinghua / PKU backgrounds
- Collaboration with leading institutions and companies worldwide
- Dedicated to low-cost, high-efficiency drug development and translation
Honors & Qualifications
Recipient of grants from the China/Beijing Returnee Entrepreneurship Support Program, Beijing Talent Program, and Yicheng Talent Program. Our R&D team includes 4 mentors and 6 postdocs, with 100% of researchers graduating from top institutions in China, the U.S., and the U.K. The team includes three Yiqilin Talents and two overseas talent settle-ins. From 2024–2025, JWE obtained qualifications such as National Technology-Based SME, Zhongguancun High-Tech Enterprise, and Beijing Natural Science Foundation Supporting Unit. The team has won awards including Top 10 in the Zhongguancun International Frontier Technology Competition (Synthetic Biology), First Prize for Scientific and Technological Progress from the Henan Provincial Department of Education, and Hefei Tech Innovation Cup Top 10. Our internationally original IMMUNE IP platform has been licensed to U.S. distributor EzWy LLC.
Over the next five years, the company aims to transition from a biotech firm to a biopharma unicorn and accelerate into the global pharmaceutical market.
Our Advantages in HLA Neoantigen Development
Cost is only 10% of traditional methodsJWE Team
-
Jiang Wei Founder / CEO / CSO
Former lecturer at Stanford University; Ph.D. from the University of Pennsylvania; B.S. from Tsinghua University. Inventor of yeast display patents and international patent for narcolepsy detection.
-
Yan Sangtian Co-Founder / CIO
Partner at an IP law firm; Ph.D. from Tsinghua University; registered Japanese patent attorney (Benrishi).
-
Gong Yunyun Partner / COO / R&D Director
Ph.D. from Peking University; postdoctoral researcher at Beihang University; extensive research in T-cell therapy mechanisms; clinical filing and translation experience in TIL and other immunotherapies.
-
Ding Xiaowen Partner / CTO
Postdoctoral researcher at Stanford University; experienced in immunology and cellular-molecular biotechnology.
